Evidence map›Paper›PMID 34122398›Full record

ArticleFrontiers in immunology2021

Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human Life.

Oludare A Odumade, Alec L Plotkin, Jensen Pak, Olubukola T Idoko, Matthew A Pettengill, Tobias R Kollmann, Al Ozonoff, Beate Kampmann, Ofer Levy, Kinga K Smolen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Oludare A OdumadePrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States.
Alec L PlotkinPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States.
Jensen PakPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States.
Olubukola T IdokoPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States.
Matthew A PettengillPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States.
Tobias R KollmannTelethon Kids Institute, University of Western Australia, Perth, WA, Australia.
Al OzonoffPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States.
Beate KampmannVaccines & Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia.
Ofer LevyPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States.
Kinga K SmolenPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, United States.
Boston Children's Hospital · USHarvard University · USBroad Institute · USLondon School of Hygiene & Tropical Medicine · GBMRC Unit the Gambia · GMThe Kids Research Institute Australia · AU

Funding

Transcriptomics to define biomarkers of neonatal vaccine immunogenicityU19AI118608 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2017 to 2021
$24.7M
NIAID NIH HHS U19 AI118608
6 · The paper itself

Abstract

Background: Human adenosine deaminases (ADAs) modulate the immune response: ADA1 Methods: In a subgroup of the EPIC002-study, clinical data and plasma samples were collected from 540 Gambian infants at four time-points: day of birth; first week of life; one month of age; and four months of age. Concentrations of total extracellular ADA, ADA1, and ADA2 were measured by chromogenic assay and evaluated in relation to clinical data. Plasma cytokines/chemokine were measured across the first week of life and correlated to ADA concentrations. Results: ADA2 demonstrated a steady rise across the first months of life, while ADA1 concentration significantly decreased 0.79-fold across the first week then increased 1.4-fold by four months of life. Males demonstrated significantly higher concentrations of ADA2 (1.1-fold) than females at four months; newborns with early-term (37 to <39 weeks) and late-term (≥41 weeks) gestational age demonstrated significantly higher ADA1 at birth (1.1-fold), and those born to mothers with advanced maternal age (≥35 years) had lower plasma concentrations of ADA2 at one month (0.93-fold). Plasma ADA1 concentrations were positively correlated with plasma CXCL8 during the first week of life, while ADA2 concentrations correlated positively with TNFα, IFNγ and CXCL10, and negatively with IL-6 and CXCL8. Conclusions: The ratio of plasma ADA2/ADA1 concentration increased during the first week of life, after which both ADA1 and ADA2 increased across the first four months of life suggesting a gradual development of Th1/Th2 balanced immunity. Furthermore, ADA1 and ADA2 were positively correlated with cytokines/chemokines during the first week of life. Overall, ADA isoforms demonstrate robust ontogeny in newborns and infants but further mechanistic studies are needed to clarify their roles in early life immune development and the correlations with sex, gestational age, and maternal age that were observed.

Indexed as

BiomarkersAdenosine DeaminaseCytokinesFemaleGambiaHumansImmunomodulationInfantInfant, NewbornIntercellular Signaling Peptides and ProteinsMalePublic Health SurveillanceT-Lymphocyte SubsetsADA2 protein, humanADA protein, humanAdenosine DeaminaseBiomarkersCytokinesIntercellular Signaling Peptides and Proteinsadenosineadenosine deaminasebiomarkerschemokinescytokinesontogenysex differences

Identifiers

PMID34122398
PMCPMC8190399
OpenAlexW3171674439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.